National Cancer Institute (NCI): Carcinoma trials

The registry lists 341 Carcinoma studies with National Cancer Institute (NCI) as lead sponsor. 10 are open to participants now and 185 have results posted.

Early Phase 1 2Phase 1 120Phase 2 220Phase 3 12No phase 18(a study in two phases counts in both)

Studies

Page 4 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00077441Phase 2
• Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and NeckCompletedNCT00077428Phase 2
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing CystectomyTerminatedNCT00072137Phase 1
• Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00071994Phase 2
• Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast CancerCompletedNCT00070252Phase 1/2
• S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerCompletedNCT00068783Phase 2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckCompletedNCT00063895Phase 1/2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00055913Phase 1/2
• Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck CancerCompletedNCT00055770Phase 1/2
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1
• Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat CancerCompletedNCT00049166Phase 1
• Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver DysfunctionCompletedNCT00047346Phase 1
• Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically RemovedTerminatedNCT00047333Phase 2
• Cancer Risk in Carriers of the Gene for Xeroderma PigmentosumCompletedNCT00046189
• Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00033618Phase 2
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerCompletedNCT00033462Phase 2
• Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck CancerTerminatedNCT00033449Phase 1
• Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the CervixCompletedNCT00031993Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• Gefitinib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT00027690Phase 2
• Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug ResistanceCompletedNCT00026663
• Thalidomide in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00025467Phase 2
• Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
• BMS-247550 in Treating Patients With Liver or Gallbladder CancerTerminatedNCT00023946Phase 2
• Ixabepilone in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00021099Phase 2
• PS-341 and Radiation to Treat Advanced Cancer of the Head and NeckCompletedNCT00011778Phase 1
• Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerCompletedNCT00006089Phase 2
• Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract CancerCompletedNCT00005831Phase 2
• The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive DiseasesCompletedNCT00005660
• Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the UrotheliumTerminatedNCT00004856Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian CancerCompletedNCT00002913Phase 1
• Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal CarcinomatosisCompletedNCT00001569Phase 1
• A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the BladderCompletedNCT00001381Phase 1
• A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical ResectionCompletedNCT00001339Phase 2
• Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal CarcinomatosisCompletedNCT00001332Phase 1